Cardiology

  • Bioresorbable stents: The future of interventional cardiology?
    Stephen G. Ellis, MD and Haris Riaz, MD
    Cleveland Clinic Journal of Medicine November 2016, 83 (11 suppl 2) S18-S23; DOI: https://doi.org/10.3949/ccjm.83.s2.03
  • Leadless cardiac pacing: What primary care providers and non-EP cardiologists should know
    Erich L. Kiehl, MD and Daniel J. Cantillon, MD, FACC, FHRS
    Cleveland Clinic Journal of Medicine November 2016, 83 (11 suppl 2) S24-S34; DOI: https://doi.org/10.3949/ccjm.83.s2.04
  • PCSK9 inhibition: A promise fulfilled?
    Khendi White, MD, Chaitra Mohan, MD and Michael Rocco, MD
    Cleveland Clinic Journal of Medicine November 2016, 83 (11 suppl 2) S36-S44; DOI: https://doi.org/10.3949/ccjm.83.s2.05
  • Fibromuscular dysplasia: Advances in understanding and management
    Ellen K. Brinza, MS and Heather L. Gornik, MD
    Cleveland Clinic Journal of Medicine November 2016, 83 (11 suppl 2) S45-S51; DOI: https://doi.org/10.3949/ccjm.83.s2.06
  • Cardiovascular disease: Innovations in devices and techniques
    Maan A. Fares, MD
    Cleveland Clinic Journal of Medicine November 2016, 83 (11 suppl 2) S9; DOI: https://doi.org/10.3949/ccjm.83.s2.01
  • Eruptive xanthoma: Warning sign of systemic disease
    Gillian Roga, MD and Madhukhara Jithendriya, DNB
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 715-716; DOI: https://doi.org/10.3949/ccjm.83a.15126

    Initial laboratory testing showed a triglyceride level of 5,742 mg/dL.

  • Update in perioperative cardiac medicine
    Steven L. Cohn, MD, MS, FACP, SFHM, Suparna Dutta, MD, MPH, Barbara A. Slawski, MD, MS, FACP, SFHM, Paul J. Grant, MD, SFHM, FACP and Gerald W. Smetana, MD, FACP
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 723-730; DOI: https://doi.org/10.3949/ccjm.83a.16076

    Risk assessment, risk reduction, antiplatelet therapy after stent placement, and bridging anticoagulation.

  • The ABCs of managing systolic heart failure: Past, present, and future
    Ike S. Okwuosa, MD, Oluseyi Princewill, MD, MPH, Chiemeke Nwabueze, MD, Lena Mathews, MD, Steven Hsu, MD, Nisha A. Gilotra, MD, Sabra Lewsey, MD, MPH, Roger S. Blumenthal, MD and Stuart D. Russell, MD
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 753-765; DOI: https://doi.org/10.3949/ccjm.83a.16006

    Digitalis, diuretics, and bedrest have given way to neurohormonal blockade and physical rehabilitation.

  • Evolution of heart failure management: Miles to go
    James B. Young, MD
    Cleveland Clinic Journal of Medicine October 2016, 83 (10) 766-768; DOI: https://doi.org/10.3949/ccjm.83a.16043

    Despite progress, too many patients still suffer, too many die too young, and the costs are still too great.

  • Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Meghana Halkar, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine September 2016, 83 (9) 675-688; DOI: https://doi.org/10.3949/ccjm.83a.15092

    After drug-eluting stent placement, at least 12 months of dual antiplatelet therapy is recommended. Would longer be better?

Pages